Stritch School of Medicine, Loyola University Chicago, IL, USA.
Neurol Clin. 2013 Aug;31(3):677-704. doi: 10.1016/j.ncl.2013.03.006. Epub 2013 May 10.
This article reviews some of the current literature in support or against extension of the intravenous tissue plasminogen activator window, use of intra-arterial therapy or devices, as well alternative pharmacologic therapies that may extend the window for treatment of patients with acute ischemic stroke, with consideration of the relative risk of thrombolytic complications, factors for worse outcomes, and unclear stroke onset, as seen in patients with wake-up stroke. The issue of newer concomitant antithrombotic therapies as they affect the decision for acute ischemic stroke thrombolytic therapy is also explored.
本文回顾了一些目前的文献，以支持或反对扩大静脉组织型纤溶酶原激活剂治疗窗、使用动脉内治疗或器械，以及可能延长急性缺血性脑卒中患者治疗窗口的替代药物治疗，同时考虑溶栓并发症的相对风险、预后不良的因素和不明原因的卒中发作，如觉醒性卒中患者所见。还探讨了新型伴随抗血栓治疗对急性缺血性脑卒中溶栓治疗决策的影响。
